These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
372 related articles for article (PubMed ID: 10188897)
1. Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancer. Hohaus S; Funk L; Martin S; Schlenk RF; Abdallah A; Hahn U; Egerer G; Goldschmidt H; Schneeweiss A; Fersis N; Kaul S; Wallwiener D; Bastert G; Haas R Br J Cancer; 1999 Mar; 79(9-10):1500-7. PubMed ID: 10188897 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and toxicity of sequential high-dose therapy with peripheral blood stem cell support in patients with high-risk breast cancer. Hohaus S; Wallwiener D; Martin S; Voso MT; Huober J; Fersis N; Bastert G; Haas R Semin Oncol; 1998 Apr; 25(2 Suppl 4):7-11; discussion 45-8. PubMed ID: 9578056 [TBL] [Abstract][Full Text] [Related]
3. Adjuvant high-dose therapy with peripheral blood stem cell support for patients with high-risk breast cancer. Hohaus S; Martin S; Schneeweiss A; Voso MT; Schlenk RF; Wallwiener D; Bastert G; Haas R Cancer Chemother Pharmacol; 1999; 44 Suppl():S13-7. PubMed ID: 10602904 [TBL] [Abstract][Full Text] [Related]
4. Tandem high-dose therapy with ifosfamide, epirubicin, carboplatin and peripheral blood stem cell support is an effective adjuvant treatment for high-risk primary breast cancer. Haas R; Schmid H; Hahn U; Hohaus S; Goldschmidt H; Murea S; Kaufmann M; Wannenmacher M; Wallwiener D; Bastert G; Hunstein W Eur J Cancer; 1997 Mar; 33(3):372-8. PubMed ID: 9155519 [TBL] [Abstract][Full Text] [Related]
5. Adjuvant treatment of high-risk stage II breast cancer with doxorubicin followed by high-dose chemotherapy and autologous stem-cell transplantation: a single-institution experience with 132 consecutive patients. Stemmer SM; Hardan I; Raz H; Adamou AK; Inbar M; Gottfried M; Merrick Y; Cohen Y; Sulkes A; Ben-Baruch N; Pfeffer RP; Brenner HJ; Rizel S Bone Marrow Transplant; 2003 Apr; 31(8):655-61. PubMed ID: 12692605 [TBL] [Abstract][Full Text] [Related]
6. Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer. Schrama JG; Baars JW; Holtkamp MJ; Schornagel JH; Beijnen JH; Rodenhuis S Bone Marrow Transplant; 2001 Jul; 28(2):173-80. PubMed ID: 11509935 [TBL] [Abstract][Full Text] [Related]
7. Adjuvant treatment of high-risk breast cancer using multicycle high-dose chemotherapy and filgrastim-mobilized peripheral blood progenitor cells. Basser RL; To LB; Begley CG; Juttner CA; Maher DW; Szer J; Cebon J; Collins JP; Russell I; Olver I Clin Cancer Res; 1995 Jul; 1(7):715-21. PubMed ID: 9816037 [TBL] [Abstract][Full Text] [Related]
8. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
9. Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95. ; Basser RL; O'Neill A; Martinelli G; Green MD; Peccatori F; Cinieri S; Coates AS; Gelber RD; Aebi S; Castiglione-Gertsch M; Viale G; Price KN; Goldhirsch A J Clin Oncol; 2006 Jan; 24(3):370-8. PubMed ID: 16421418 [TBL] [Abstract][Full Text] [Related]
10. High-dose sequential epirubicin and cyclophosphamide with peripheral blood stem cell support for advanced breast cancer: results of a phase II study. Cottu PH; Extra JM; Espie M; Marolleau JP; de Roquancourt A; Makke J; Miclea JM; Laurence V; Mayeur D; Lerebours F; Cuvier C; Marty M Br J Cancer; 2001 Nov; 85(9):1240-6. PubMed ID: 11720455 [TBL] [Abstract][Full Text] [Related]
11. First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial). Viens P; Palangié T; Janvier M; Fabbro M; Roché H; Delozier T; Labat JP; Linassier C; Audhuy B; Feuilhade F; Costa B; Delva R; Cure H; Rousseau F; Guillot A; Mousseau M; Ferrero JM; Bardou VJ; Jacquemier J; Pouillart P Br J Cancer; 1999 Oct; 81(3):449-56. PubMed ID: 10507769 [TBL] [Abstract][Full Text] [Related]
12. [High-dosage chemotherapy and the autologous transplantation of peripheral hematopoietic progenitor cells in breast cancer: the initial results, analysis of toxicity and the necessary support means]. Sola Rocabert C; Mesía R; Mendoza L; Tabernero JM; Amill B; Maroto P; Bellet M; Ojeda B; Alonso MC; Verger G Med Clin (Barc); 1995 Oct; 105(11):407-11. PubMed ID: 7475451 [TBL] [Abstract][Full Text] [Related]
13. Poor outcome of patients with resectable breast cancer receiving adjuvant high-dose sequential chemotherapy following preoperative treatment. Zambelli A; Da Prada GA; Pedrazzoli P; Ponchio L; Robustelli della Cuna G Anticancer Res; 1999; 19(3B):2373-6. PubMed ID: 10472359 [TBL] [Abstract][Full Text] [Related]
14. Multimodality treatment including early high-dose chemotherapy with peripheral blood stem cell transplantation in limited-disease small cell lung cancer. Brugger W; Fetscher S; Hasse J; Frommhold H; Pressler K; Mertelsmann R; Engelhardt R; Kanz L Semin Oncol; 1998 Feb; 25(1 Suppl 2):42-8. PubMed ID: 9535211 [TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582 [TBL] [Abstract][Full Text] [Related]
16. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial. Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J; J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969 [TBL] [Abstract][Full Text] [Related]
17. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. Peters WP; Rosner GL; Vredenburgh JJ; Shpall EJ; Crump M; Richardson PG; Schuster MW; Marks LB; Cirrincione C; Norton L; Henderson IC; Schilsky RL; Hurd DD J Clin Oncol; 2005 Apr; 23(10):2191-200. PubMed ID: 15767638 [TBL] [Abstract][Full Text] [Related]
18. Acute and late toxicity following adjuvant high-dose chemotherapy for high-risk primary operable breast cancer--a quality assessment study. Svane IM; Homburg KM; Kamby C; Nielsen DL; Roer O; Sliffsgaard D; Johnsen HE; Hansen SW Acta Oncol; 2002; 41(7-8):675-83. PubMed ID: 14651213 [TBL] [Abstract][Full Text] [Related]
19. Early intensive and myeloablative adjuvant chemotherapy in women with high-risk breast cancer. Wörmann B; Meden H; Riggert J; Humpe A; Wulf G; Koch B; Köhler M; Kuhn W; Hiddemann W Anticancer Res; 1998; 18(3C):2237-41. PubMed ID: 9703793 [TBL] [Abstract][Full Text] [Related]
20. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. Rodenhuis S; Bontenbal M; Beex LV; Wagstaff J; Richel DJ; Nooij MA; Voest EE; Hupperets P; van Tinteren H; Peterse HL; TenVergert EM; de Vries EG; N Engl J Med; 2003 Jul; 349(1):7-16. PubMed ID: 12840087 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]